Key Finding: Neurocrine Biosciences (NBIX) is a neuroscience-focused biopharma with robust growth from its flagship INGREZZA product, recent rare-disease expansion via the Soleno acquisition, and strong analyst support, trading near record highs as of the latest close.
Live Stock Price (as of July 10, 2026 close)
After-hours: ~$177.40 (+0.16%)
Volume: ~1.05M shares
Market Cap: ~$17.81B
Day Range: $174.21 – $181.18
52-Week Range: $122.14 – $181.18
Open: $181.00
Previous Close: $180.55
Fact: Price data sourced from Yahoo Finance, company IR, Morningstar, and TradingView (minor variances of $0.01–$0.10 across sources).
Limitation: This reflects the July 10 close; markets are closed as of July 11, 2026. Stock prices are volatile and not guaranteed to match real-time quotes.
Stock Performance
| Period |
NBIX Return |
S&P 500 Return |
Notes |
| YTD (2026) |
+24.87% |
+10.66% |
Outperformance driven by earnings beats and pipeline progress |
| 1-Year |
+31.27% |
+20.62% |
Recent surge from ~$135 to near $180 |
| 3-Year |
+85.34% |
+71.80% |
Strong long-term growth |
| 5-Year |
+78.84% |
+73.37% |
Solid but with volatility typical of biotech |
Recent Highlights:
- Hit new 52-week high of $181.18 on July 10, 2026
- Significant institutional inflows noted since May 2026
- All-time closing high around $180.55 (July 9, 2026)
Fact: Performance data from Yahoo Finance and Macrotrends.
Interpretation: Outperformance reflects commercial success of INGREZZA and acquisition momentum, though biotech stocks remain sensitive to clinical/regulatory news.
Uncertainty: Past performance does not predict future results; no dividends paid.
Company Overview
Neurocrine Biosciences, Inc. discovers, develops, and commercializes pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders. Headquartered in San Diego, California, with approximately 2,000 employees.
Key Approved Products
- INGREZZA (valbenazine) — Tardive dyskinesia and chorea associated with Huntington’s disease (primary revenue driver)
- CRENESSITY (crinecerfont) — Classic congenital adrenal hyperplasia (first new treatment in decades)
- Orilissa / Oriahnn (in collaboration with AbbVie) — Endometriosis and uterine fibroids
- VYKAT XR (diazoxide choline) — Hyperphagia in Prader-Willi syndrome (added via Soleno acquisition)
Pipeline Highlights
Multiple mid-to-late stage candidates in movement disorders, major depressive disorder, schizophrenia, epilepsy, and obesity/metabolic diseases.
Fact: Product and pipeline details from company website, Yahoo Finance profile, and Wikipedia.
Limitation: Pipeline success is not guaranteed; clinical trials carry inherent risks of failure.
Company History
- 1992: Founded in San Diego by Wylie Vale (Salk Institute), Lawrence Steinman (Stanford), Larry Bock, and Kevin Gorman, focusing on CRF antagonists and neuroscience.
- 1996: IPO on NASDAQ (raised $34.2M).
- 2017: FDA approval of INGREZZA for tardive dyskinesia — transformative commercial product.
- 2024–2025: Leadership transition; Kyle Gano named CEO (Oct 2024).
- May 2026: Announced and subsequently closed acquisition of Soleno Therapeutics (~$2.9B equity value) to expand rare disease portfolio with VYKAT XR.
- 2026: Continued pipeline advancement and strong commercial execution.
Fact: Historical timeline from company “About Us” page, Wikipedia, and press releases.
Interpretation: Evolution from early-stage research to commercial-stage company with diversified portfolio.
Recent News (2026)
- July 2026: Q2 2026 earnings conference call and webcast scheduled for July 30, 2026.
- July 2026: Multiple analyst price target raises (RBC to $195, UBS to $208, others higher); consensus ~$195–$199 with “Strong Buy” rating from ~22 analysts.
- July 2026: Initiation of Phase 2 study of crinecerfont in pediatric CAH patients under 4 years old; additional data presentations at ENDO 2026.
- May 2026: Q1 2026 results: Net product sales $811M (+44% YoY); beat estimates; reaffirmed 2026 INGREZZA guidance $2.7–2.8B; Soleno acquisition announced/closed.
- June 2026: Positive data readouts and presentations supporting pipeline de-risking.
Fact: News aggregated from PR Newswire, Seeking Alpha, TipRanks, and Yahoo Finance.
Interpretation: Strong momentum from commercial execution and M&A, reflected in upward analyst revisions.
Uncertainty: Future earnings, clinical outcomes, and regulatory decisions remain unknown.
Analyst Snapshot
Consensus Rating: Strong Buy
Avg. 12-Month Target: ~$195–$199
Implied Upside: ~10–12% from $177.11
19 Buy / 3 Hold / 0 Sell (recent 3 months)
High targets up to $250.65; low $144
Interpretation: Wall Street views the stock favorably due to diversified growth and pipeline.
Limitation: Analyst targets are opinions and frequently revised; not investment advice.